A Phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide combined with trastuzumab and Pertuzumab in HER-2 positive breast cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Pertuzumab; Trastuzumab
Indications Breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
Focus Therapeutic Use

13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
03 Dec 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com